This Article Full Text Full Text (PDF) All Versions of this Article: 110/23/3594    most recent 01.CIR.0000148781.87906.C0v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Parker, A. C. Articles by Fay, W. P. Search for Related Content PubMed PubMed Citation Articles by Parker, A. C. Articles by Fay, W. P. Related Collections Fibrinogen/fibrin Coagulation and fibronolysis Thrombophilia Thrombosis risk factors Fibrinolysis Related Article

(Circulation. 2004;110:3594-3598.)
© 2004 American Heart Association, Inc.

Vascular Medicine

Factor V^Leiden Inhibits Fibrinolysis In Vivo

Andrew C. Parker, BS; Lakshmi V. Mundada, MS; Alvin H. Schmaier, MD; William P. Fay, MD

From the Department of Internal Medicine, University of Michigan Medical School, Ann Arbor.

Correspondence to William Fay, MD, University of Michigan, 7301 MSRB III, 1150 W Medical Center Dr, Ann Arbor, MI 48109-0644. E-mail wfay{at}umich.edu

Received June 8, 2004; revision received September 12, 2004; accepted September 24, 2004.

Background— Factor V^Leiden (fV^Leiden) predisposes to thrombosis by enhancing thrombin formation. This study tested the hypothesis that fV^Leiden inhibits fibrinolysis in vivo.

Methods and Results— Radiolabeled clots were injected into the jugular veins of wild-type mice and mice heterozygous (fV^+/Q) or homozygous (fV^Q/Q) for fV^Leiden. Mean percent clot lysis 5 hours later was significantly reduced in fV^Q/Q mice (14.3±3.6%, n=13) compared with wild-type mice (40.2±7.0%, n=17; P<0.01) and intermediate in fV^+/Q mice (29.4±8.7%, n=9; P<0.03 versus fV^Q/Q, P=0.36 versus wild type). The rate of in vitro lysis of plasma clots prepared from fV^+/Q or fV^Q/Q mice was significantly slower than that of wild-type plasma clots, whereas in vitro clot lysis did not differ significantly between groups after inhibiting thrombin-activatable fibrinolysis inhibitor.

Conclusions— fV^Leiden inhibits fibrinolysis in vivo, suggesting an additional pathway by which this mutation promotes thrombosis.

Key Words: fibrin • fibrinolysis • coagulation • thrombosis • thrombolysis

Related Article:

Issue Highlights
Circulation 2004 110: 3503. [Full Text]

This article has been cited by other articles:

				W. P. Fay, N. Garg, and M. Sunkar Vascular Functions of the Plasminogen Activation System Arterioscler. Thromb. Vasc. Biol., June 1, 2007; 27(6): 1231 - 1237. [Abstract] [Full Text] [PDF]

				L. O. Mosnier and B. N. Bouma Regulation of Fibrinolysis by Thrombin Activatable Fibrinolysis Inhibitor, an Unstable Carboxypeptidase B That Unites the Pathways of Coagulation and Fibrinolysis Arterioscler. Thromb. Vasc. Biol., November 1, 2006; 26(11): 2445 - 2453. [Abstract] [Full Text] [PDF]

				S. R. Lentz Another Lesson From the Factor V Leiden Mouse: Thrombin Generation Drives Arterial Disease Circulation, April 12, 2005; 111(14): 1733 - 1734. [Full Text] [PDF]